Fierce Biotech Logo Fierce Biotech Logo Fierce Biotech Logo

Highly-Personalized Therapies & Cancer Management

Available on-demand
60 Minutes

Through collaborations between biopharma and diagnostic developers the field of oncology is advancing to ensure highly-personalized therapies and diagnostics are a part of the next gold standard of care. While the utility of monitoring molecular residual disease (MRD) has been explored in several indications, monitoring disease recurrence of low tumor mutational burden (TMB) cancers remains a challenge. In these cases, an ultra-sensitive, tumor-informed ctDNA-based MRD detection platform is needed.

In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. The results indicated changes in ctDNA levels relative to baseline following treatment were detected prior to confirmation of clinical response by RECIST 1.1 and correlated well with disease status.

About Personalis:
Personalis is transforming the active management of cancer through more personalized testing. 

About Geneos Therapeutics:
Geneos Therapeutics a clinical stage biotherapeutic company, believes that personalized therapies will serve an important role in new treatment paradigms for cancer.


Daniel Norton

Daniel Norton

Dan Norton is currently Associate Director of Product Management with a focus on Liquid Biopsies at Personalis, following a role as Senior Product Manager focused on Immuno-Oncology. Prior to this, Dan had several product management and business development roles at Bio-Rad Laboratories, Illumina, Althea Technologies and Bayer Healthcare. Dan has an MBA from University California, San Diego and a BS from University California, Los Angeles.

Jian Yan

Jian Yan

Dr. Yan leads the research team at Geneos, and brings with her over 15 years of experience in leading preclinical research programs for the development of novel immunotherapies. Prior to joining Geneos, she led teams at NEUVOGEN and INOVIO Pharmaceuticals. Dr. Yan received her Ph. D. in Molecular Biology and Genetics from Fudan University through a co-training program between Fudan University and Yale University, and started her career as a postdoctoral researcher at University of Pennsylvania.

Register here to watch on-demand!

60 Minutes